TheBrief.Health
FDA’s Red No. 3 ban will phase the dye out of foods and medicines by 2027, prompting reformulations while reassuring consumers about minimal health risk.
Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity TheBrief.Health-yhteisöön!
Kokeilun jälkeen 7,99 € / kuukausi. · Peru milloin tahansa.
518 jaksot
Beyond the Prescription Pad: Breast Cancer Survivorship via Combined Lifestyle Interventions
A structured low-GI Mediterranean diet, daily brisk walking, and vitamin D supplementation significantly reduced recurrence risk in HR-positive breast cancer survivors while improving metabolic health.
Adagio Files FDA Submission For Ventricular Ablation System
Adagio Medical’s FDA submission for its ultra-low temperature ventricular ablation system could expand treatment options for drug-refractory ventricular tachycardia, offering deeper lesion creation, fewer ICD shocks, reduced antiarrhythmic dependence, and improved procedural outcomes.
Ban Of Red Food Dye 3: Safety Implications For Families
Reflow Medical’s Retrievable Coronary Drug‑Eluting Stent Shows Early Promise in In‑Stent Restenosis
Reflow Medical’s retrievable sirolimus-eluting coronary scaffold aims to treat in-stent restenosis without permanent metal, potentially improving vessel healing while preserving future treatment options.
Neurovalens CEO Outlines Noninvasive Neuromodulation Plans
Neurovalens’ Modius platform brings noninvasive neuromodulation into clinical practice, offering home-based FDA-authorized therapies for insomnia, anxiety, PTSD, and weight management, while facing evidence, reimbursement, and adoption challenges.
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity TheBrief.Health-yhteisöön!